MKI67 and non-small cell lung carcinoma: Assessment of the correlation between Ki-67 and first-line therapeutic outcomes in advanced or postoperative-recurrent NSCLC patients with KRAS-mutant status, we interestingly found that the Ki-67 expression levels in the KRAS mutation group were higher than KRAS wildtype, and the OS of the KRAS-mutant group was shorter than in the KRAS-wildtype group.